488 results on '"Hudis, Clifford"'
Search Results
2. Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
3. Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer
4. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection
5. Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
6. RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
7. Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score
8. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)
9. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials
10. Immunization of Metastatic Breast Cancer Patients with a Fully Synthetic Globo H Conjugate: A Phase I Trial
11. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer
12. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update
13. Monosomy 17 in potentially curable HER2-amplified breast cancer: prognostic and predictive impact
14. Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors
15. A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer
16. Big data: Are large prospective randomized trials obsolete in the future?
17. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
18. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance)
19. Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302)
20. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis
21. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer
22. 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer
23. Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance)
24. Estimating the OncotypeDX score: validation of an inexpensive estimation tool
25. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update
26. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)
27. A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer
28. A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901
29. Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020)
30. Obesity and Cancer: Concepts and Challenges
31. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype
32. Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer
33. Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow‐up
34. Serum N-Telopeptide and Bone-Specific Alkaline Phosphatase Levels in Patients With Osteonecrosis of the Jaw Receiving Bisphosphonates for Bone Metastases
35. Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial)
36. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer
37. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints
38. Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901
39. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2⁺ breast cancer patients
40. Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research
41. Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer
42. Bone Scans, Bisphosphonates, and a Lack of Acute Changes Within the Mandible
43. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis
44. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer
45. Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval
46. Dose Dense Cyclophosphamide, Methotrexate, Fluorouracil is Feasible at 14-Day Intervals: A Pilot Study of Every-14-Day Dosing as Adjuvant Therapy for Breast Cancer
47. Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer
48. Intravenous Bisphosphonate Therapy Does Not Acutely Alter Nuclear Bone Scan Results
49. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
50. Postmastectomy intensity modulated radiation therapy following immediate expander-implant reconstruction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.